Skip to content

MARKER THERAPEUTICS, INC.: net income or loss

Net income or loss for MARKER THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.

All MARKER THERAPEUTICS, INC. financial histories

What this measure means

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2000-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Net income or loss in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2025-01-012025-12-31-12,163,620USD2026-03-1810-K · 0001104659-26-031274
2024-01-012024-12-31-10,731,315USD2026-03-1810-K · 0001104659-26-031274
2023-01-012023-12-31-8,236,814USD2025-03-3110-K · 0001410578-25-000549
2022-01-012022-12-31-29,930,694USD2024-03-2610-K · 0001410578-24-000297
2021-01-012021-12-31-41,878,871USD2023-03-2210-K · 0001410578-23-000324
2020-01-012020-12-31-28,706,070USD2022-03-1710-K · 0001410578-22-000418
2019-01-012019-12-31-21,427,964USD2021-03-0910-K · 0001104659-21-033855
2018-01-012018-12-31-147,957,910USD2020-03-1210-K · 0001104659-20-032463
2017-01-012017-12-31-10,982,177USD2019-03-1510-K · 0001144204-19-014350
2016-01-012016-12-31-2,455,381USD2018-03-2310-K · 0001144204-18-016734
2015-01-012015-12-31-34,066,390USD2017-03-1410-K · 0001144204-17-014490
2014-01-012014-12-31-30,883,096USD2016-04-1410-K · 0001193125-16-541539
2013-01-012013-12-31-5,532,552USD2015-04-1510-K · 0001424884-15-000039
2012-01-012012-12-31-5,857,943USD2013-05-1510-K · 0001554757-13-000319
2011-01-012011-12-31-2,028,941USD2013-05-1510-K · 0001554757-13-000319
2010-01-012010-12-31-3,532,623USD2012-04-1610-K · 0001424884-12-000026
2009-01-012009-12-31-17,348,546USD2012-04-1610-K · 0001424884-12-000026
2008-01-012008-12-31-2,195,939USD2012-04-1610-K · 0001424884-12-000026
2007-01-012007-12-31-3,891,411USD2012-04-1610-K · 0001424884-12-000026
2006-01-012006-12-31-1,304,387USD2012-04-1610-K · 0001424884-12-000026
2005-01-012005-12-31-985,599USD2012-04-1610-K · 0001424884-12-000026
2004-01-012004-12-31-2,683,105USD2012-04-1610-K · 0001424884-12-000026
2003-01-012003-12-31-5,778,905USD2012-04-1610-K · 0001424884-12-000026
2002-01-012002-12-31-2,284,709USD2012-04-1610-K · 0001424884-12-000026
2001-01-012001-12-31-671,986USD2012-04-1610-K · 0001424884-12-000026
2000-01-012000-12-31-935,332USD2012-04-1610-K · 0001424884-12-000026

Related financial histories

Inspect the source

Entity
MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured
2026-09-20T05:22:11.393Z
SEC response SHA-256
11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))